SCOP Search:   
        by sunid, keyword
QuickSearch:   
by PDB,NDB,UniProt,PROSITE Code or Search Term(s)  
(use 'Shift Left-Click' to collapse/expand all levels downwards; use 'Control Left-Click' to collapse/expand all levels upwards)
 
(-)
Class: All alpha proteins (14657)
(-)
Fold: Cyclin-like (137)
(-)
Superfamily: Cyclin-like (137)
(-)
Family: Cyclin (117)
(-)
Protein domain: automated matches (10)
(-)
Cow (Bos taurus) [TaxId: 9913] (3)
3TNWB:176-308; B:309-432; D:176-308; D:309-432STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
4BCOB:175-308; B:309-432; D:177-308; D:309-432STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR
4BCQB:176-308; D:176-308; D:309-431; B:309-432STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR
(-)
Human (Homo sapiens) [TaxId: 9606] (5)
3MIAB:7-150; B:151-261CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH ATP-BOUND HUMAN P-TEFB
4BCKB:176-308; B:309-432; D:178-308; D:309-430STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR
4BCMB:176-308; B:309-432; D:176-308; D:309-428STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR
4BCNB:176-308; B:309-432; D:177-308; D:309-431STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR
4BCPB:176-308; D:176-308; D:309-432; B:309-432STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR
(-)
Mouse (Mus musculus) [TaxId: 10090] (2)
4I3ZB:175-309; B:310-431; D:175-309; D:310-431STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
4II5B:175-309; B:310-430; D:175-309; D:310-431STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
(-)
Protein domain: CDK5 activator 1 (NCK5a, p25) (5)
(-)
Human (Homo sapiens) [TaxId: 9606] (5)
1H4LD:; E:STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
1UNGD:; E:STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE, ALOISINE AND INDIRUBIN.
1UNHD:; E:STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE, ALOISINE AND INDIRUBIN.
1UNLD:; E:STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE, ALOISINE AND INDIRUBIN.
3O0GD:; E:CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
(-)
Protein domain: Cyclin A (82)
(-)
Cow (Bos taurus) [TaxId: 9913] (9)
1VINA:181-308; A:309-432BOVINE CYCLIN A3
2G9XB:171-309; B:310-432; D:171-309; D:310-432STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
3BHTB:171-308; B:309-432; D:171-308; D:309-432STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
3BHUB:171-308; B:309-432; D:171-308; D:309-432STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
3BHVB:171-308; B:309-432; D:171-308; D:309-432STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
3DDPB:171-309; B:310-432; D:171-309; D:310-438STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
3DDQB:171-309; B:310-432; D:171-309; D:310-439STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
3DOGB:171-309; B:310-432; D:171-309; D:310-434STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
3MY5B:171-308; D:171-308; D:309-432; B:309-432CDK2/CYCLINA IN COMPLEX WITH DRB
(-)
Human (Homo sapiens) [TaxId: 9606] (73)
1E9HB:175-309; B:310-432; D:175-309; D:310-432THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
1FINB:173-309; B:310-432; D:173-309; D:310-432CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
1FVVB:173-309; B:310-432; D:173-309; D:310-432THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
1GY3B:175-309; B:310-432; D:175-309; D:310-432PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE
1H1PB:175-309; B:310-432; D:175-309; D:310-432STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
1H1QB:175-309; B:310-432; D:175-309; D:310-432STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
1H1RB:175-309; B:310-432; D:175-309; D:310-432STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
1H1SB:175-309; B:310-432; D:175-309; D:310-432STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
1H24B:175-309; B:310-432; D:175-309; D:310-432CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
1H25B:175-309; B:310-432; D:175-309; D:310-432CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
1H26B:175-309; D:175-309; D:310-432; B:310-432CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
1H27B:175-309; B:310-432; D:175-309; D:310-432CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
1H28B:175-309; B:310-432; D:175-309; D:310-432CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
1JSTB:175-309; B:310-432; D:175-309; D:310-432PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
1JSUB:175-309; B:310-432P27(KIP1)/CYCLIN A/CDK2 COMPLEX
1OGUB:178-309; B:310-432; D:178-309; D:310-432STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
1OI9B:175-309; B:310-432; D:178-309; D:310-430STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
1OIUB:177-309; B:310-432; D:177-309; D:310-432STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
1OIYB:175-309; B:310-432; D:175-309; D:310-432STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
1OKVB:175-309; B:310-432; D:173-309; D:310-432CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
1OKWB:175-309; B:310-432; D:175-309; D:310-432CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
1OL1B:175-309; B:310-432; D:175-309; D:310-432CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
1OL2B:175-309; B:310-432; D:175-309; D:310-432CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
1P5EB:175-309; B:310-432; D:175-309; D:310-432THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4,5,6,7-TETRABROMOBENZOTRIAZOLE (TBS)
1PKDB:175-309; B:310-432; D:175-309; D:310-432THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN A
1QMZB:175-309; B:310-432; D:175-309; D:310-432PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
1URCB:175-309; B:310-432; D:175-309; D:310-432CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
1VYWB:175-309; B:310-432; D:178-309; D:310-432STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
2BKZB:176-309; B:310-432; D:178-309; D:310-432STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
2BPMB:175-309; B:310-432; D:178-309; D:310-432STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
2C4GB:175-309; B:310-432; D:175-309; D:310-432STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
2C5NB:175-309; B:310-432; D:175-309; D:310-432DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2C5OB:175-309; B:310-432; D:175-309; D:310-432DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2C5VB:175-309; B:310-432; D:175-309; D:310-432DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2C5XB:175-309; B:310-432; D:175-309; D:310-432DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2C6TB:175-309; B:310-432; D:175-309; D:310-432CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2CCHB:181-308; B:309-432; D:181-308; D:309-431THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA-LINKED ATP ANALOGUE
2CCIB:181-308; B:309-432; D:181-308; D:309-432CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
2CJMB:176-309; B:310-432; D:176-309; D:310-432MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
2I40B:175-309; B:310-431; D:178-309; D:310-432CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
2IW6B:176-309; B:310-432; D:178-309; D:310-432STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2IW8B:176-309; B:310-432; D:178-309; D:310-432STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V-H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
2IW9B:176-309; B:310-432; D:178-309; D:310-432STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2UUEB:175-309; B:310-432; D:175-309; D:310-432REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2UZBB:175-309; B:310-432; D:175-309; D:310-432CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2UZDB:175-309; B:310-432; D:175-309; D:310-432CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2UZEB:175-309; B:310-432; D:175-309; D:310-432CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2UZLB:176-309; B:310-432; D:176-309; D:310-432CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2V22B:175-309; B:310-432; D:175-309; D:310-432REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2WEVB:175-309; B:310-432; D:175-309; D:310-432TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2WFYB:176-309; B:310-432; D:173-309; D:310-432TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2WHBB:175-309; B:310-432; D:175-309; D:310-432TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2WIHB:176-309; B:310-432; D:176-309; D:310-432STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
2WIPB:175-309; B:310-432; D:178-309; D:310-432STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-H] QUINAZOLINE-3-CARBOXYLIC ACID
2WPAB:175-309; B:310-432; D:179-309; D:310-432OPTIMISATION OF 6,6-DIMETHYL PYRROLO 3,4-C PYRAZOLES: IDENTIFICATION OF PHA-793887, A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
2WXVB:176-309; B:310-432; D:176-309; D:310-432STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(4,3-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
3EIDB:176-309; B:310-432; D:178-309; D:310-432CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
3EJ1B:181-308; B:309-432; D:181-308; D:309-432CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
3F5XB:177-309; B:310-432; D:178-309; D:310-432CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
4CFNB:177-309; B:310-432; D:176-309; D:310-432STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
4CFWB:175-309; B:310-432; D:176-309; D:310-432STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
4EOIB:175-309; B:310-432; D:178-309; D:310-432THR 160 PHOSPHORYLATED CDK2 K89D, Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
4EOJB:176-309; B:310-432; D:176-309; D:310-431THR 160 PHOSPHORYLATED CDK2 H84S, Q85M, K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
4EOKB:175-309; B:310-432; D:176-309; D:310-431THR 160 PHOSPHORYLATED CDK2 H84S, Q85M, K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
4EOLB:176-309; B:310-432; D:176-309; D:310-431THR 160 PHOSPHORYLATED CDK2 H84S, Q85M, K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
4EOMB:176-309; B:310-432; D:176-309; D:310-429THR 160 PHOSPHORYLATED CDK2 H84S, Q85M, Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
4EONB:176-309; B:310-432; D:175-309; D:310-431THR 160 PHOSPHORYLATED CDK2 H84S, Q85M, Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
4EOOB:175-309; B:310-432; D:176-309; D:310-429THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
4EOPB:176-309; D:175-309; D:310-429; B:310-432THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
4EOQB:176-309; B:310-432; D:176-309; D:310-429THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
4EORB:176-309; B:310-432; D:175-309; D:310-429THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
4EOSB:176-309; B:310-432; D:175-309; D:310-429THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
4FX3B:176-309; B:310-432; D:175-309; D:310-432CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
(-)
Protein domain: Cyclin H (mcs2) (2)
(-)
Human (Homo sapiens) [TaxId: 9606] (2)
1JKWA:11-161; A:162-287STRUCTURE OF CYCLIN MCS2
1KXUA:11-161; A:162-286CYCLIN H, A POSITIVE REGULATORY SUBUNIT OF CDK ACTIVATING KINASE
(-)
Protein domain: Cyclin K (1)
(-)
Human (Homo sapiens) [TaxId: 9606] (1)
2I53A:14-157; A:158-267CRYSTAL STRUCTURE OF CYCLIN K
(-)
Protein domain: Cyclin T1 (8)
(-)
Human (Homo sapiens) [TaxId: 9606] (8)
2PK2A:151-263; A:8-150; B:151-263; B:8-150; C:151-263; C:8-150; D:151-263; D:8-150CYCLIN BOX STRUCTURE OF THE P-TEFB SUBUNIT CYCLIN T1 DERIVED FROM A FUSION COMPLEX WITH EIAV TAT
3BLHB:151-259; B:5-150CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1
3BLQB:151-259; B:9-150CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH ATP
3BLRB:151-259; B:9-150CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH FLAVOPIRIDOL
3MY1B:8-150; B:151-259STRUCTURE OF CDK9/CYCLINT1 IN COMPLEX WITH DRB
3TN8B:8-150; B:151-259CDK9/CYCLIN T IN COMPLEX WITH CAN508
4BCHB:8-150; B:151-259STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4-HETEROARYL-PYRIMIDINE INHIBITOR
4IMYB:8-150; B:151-257; D:7-150; D:151-257; F:8-150; F:151-256THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
(-)
Protein domain: Cyclin-T2 (1)
(-)
Human (Homo sapiens) [TaxId: 9606] (1)
2IVXA:7-149; A:150-262; B:9-149; B:150-263CRYSTAL STRUCTURE OF HUMAN CYCLIN T2 AT 1.8 A RESOLUTION (CASP TARGET)
(-)
Protein domain: G1/S-specific cyclin-E1 (1)
(-)
Human (Homo sapiens) [TaxId: 9606] (1)
1W98B:228-357; B:88-227THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
(-)
Protein domain: Viral cyclin (7)
(-)
Herpesvirus saimiri [TaxId: 10381] (5)
1BU2A:22-148; A:149-250X-RAY STRUCTURE OF A VIRAL CYCLIN FROM HERPESVIRUS SAIMIRI
1JOWA:9-148; A:149-254CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN CDK6 AND A VIRAL CYCLIN
1XO2A:9-148; A:149-254CRYSTAL STRUCTURE OF A HUMAN CYCLIN-DEPENDENT KINASE 6 COMPLEX WITH A FLAVONOL INHIBITOR, FISETIN
2EUFA:8-148; A:149-254X-RAY STRUCTURE OF HUMAN CDK6-VCYCLIN IN COMPLEX WITH THE INHIBITOR PD0332991
2F2CA:8-148; A:149-254X-RAY STRUCTURE OF HUMAN CDK6-VCYCLINWITH THE INHIBITOR AMINOPURVALANOL
(-)
Kaposi's sarcoma-associated herpesvirus [TaxId: 37296] (1)
1G3NC:16-147; C:148-253; G:16-147; G:148-253STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
(-)
Murine herpesvirus 68 [TaxId: 33708] (1)
1F5QB:6-146; B:147-252; D:5-146; D:147-252CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2